Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Acquired in-process research and development	$ 500,000	$ 3,087,832
Research and development	7,091,163	3,805,067
General and administrative	7,790,040	3,632,920
Loss from operations	(15,381,203)	(10,525,819)
Interest income (expense), net	547,268	(64,240)
Change in fair value of convertible promissory notes	0	9,317
Other (expense) income	(2,004)	123,872
Net loss	$ (14,835,939)	$ (10,456,870)
Net income (loss) per share - basic (in dollars per share)	$ (0.93)	$ (3.69)
Net income (loss) per share - diluted (in dollars per share)	$ (0.93)	$ (3.69)
Weighted average common shares outstanding - basic (in shares)	15,966,053	2,833,674
Weighted average common shares outstanding - diluted (in shares)	15,966,053	2,833,674